- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01469884
Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients (CONCERVIC)
A Prospective, Single-center, Open-label, Pilot Study to Investigate the Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The infection by hepatitis C virus (HCV) is the leading cause of chronic liver disease in renal transplant recipients.
The prevalence of pretransplantation anti-HCV is 11% to 49%. The impact of HCV infection on patient survival after renal transplant remains controversial. Some studies also showed that patients undergoing renal transplantation anti-HCV positive are associated with a reduction in graft and patient survival.Chronic infection of HCV is associated with an increased number of infections.
In HCV positive renal transplant patients have been shown that there is an increase from four to seven times in HCV viremia after transplantation compared to pretransplant.
To prevent viral replication, immunosuppression must be adapted, involving a balance between control of viral replication and rejection.
Biochemically, the NS5A protein has been linked to increased replication of the hepatitis C virus through p70S6K phosphopeptides. Sirolimus as inhibitor of pathway mTOR/p70S6K reduced in vivo phosphorylation of NS5A phosphopeptides and thus viral replication. Moreover, the mTOR protein has been proven in vitron to have a protective role against apoptosis in HCV infected cells (WAGNER et al., 2010).
Wagner et al. (2010) showed a beneficial effect of sirolimus on viral recurrence monitored by transaminases and viral load as well as by histological data. They also reported the improved survival after liver transplantation due to hepatitis C for patients receiving sirolimus rather than calcineurin inhibitor-based regimens.
In the literature there have already been reported good virological control of HCV among liver transplant recipients after conversion to SRL and the reduction of hepatitis C virus recurrence (GALLEGO et al., 2009; BENEDETTOET al., 2010).
Everolimus has shown a potent inhibitor of mTOR and has been widely used as an immunosuppressive agent in kidney transplant, but no reported effects on HCV progression was found in the literature.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brasil, 90020090
- Irmandade da Santa Casa de Misericórdia de Porto Alegre
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria
- Age ≥ 18 years at the time of screening;
- Subjects between the first and tenth year after renal transplantation;
- Subjects with positive serology for hepatitis C;
- Subjects receiving calcineurin inhibitor (tacrolimus or cyclosporine) plus mycophenolate sodium or mofetil plus prednisone since the first month post-transplant;
- Subjects with no acute rejection episode in the last 3 month;
- Women of childbearing potential (CBP) with a negative pregnancy test at screening (urine or serum;
- Women of CBP and men with sexual partners of CBP must agree to use a medically acceptable method of contraception throughout the study. The investigator will determine which contraceptive method more effective and appropriate for each study subject. Acceptable methods of contraception include oral contraceptives, barrier methods (eg, diaphragm or condom with spermicide) and intrauterine devices.
Exclusion criteria:
- Subjects who, in the opinion of the investigator, are not able to complete the study;
- Recipients of multiple organ transplant (i.e., prior or concurrent transplantation of a non-renal allograft;
- Subjects with a calculated GFR < 30ml/min (abbreviated MDRD formula;
- Subjects with Urinary protein/creatinine > 0.5;
- Renal biopsy with score ≥ Banff grade II interstitial fibrosis and tubular atrophy (Banff 2007;
- Subjects with a history of biopsy-proven acute rejection within 12 weeks of enrollment;
- Known or suspected hypersensitivity to inhibitor of mTOR;
- Subjects with a history of primary or recurrent FSGS, membranous glomerulonephritis (MGN) or membranoproliferative glomerulonephritis (MPGN);
- Evidence of any active systemic or localized major infection;
- Use of any investigational drug or treatment up to 4 weeks before enrollment;
- Immunosuppressive therapies other than those described by this protocol;
- Planned systemic treatment with voriconazole, cisapride or ketoconazole that will not be discontinued before randomization;
- Prior treatment with aminoglycosides, amphotericin B, cisplatin or other drugs associated with renal dysfunction that is not discontinued before screening;
- Subjects with a screening total white blood cell count (WBC) ≤ 2000/mm3, hemoglobin ≤ 10g/dL and platelet count ≤ 100000/mm3;
- TGO/AST, TGP/ALT and bilirubins with values three times higher than reference values;
- Fasting triglycerides ≥ 400 mg/dL, fasting total cholesterol ≥ 350 mg/dL or LDL-cholesterol ≥ 160mg/dL despite the use of optimal lipid-lowering therapy;
- History of malignancy within 3 years before enrollment other than adequately treated basal cell or squamous cell carcinoma of the skin;
- Subjects who are known to be human immunodeficiency virus (HIV) positive or hepatitis B positive;
- Chronic hepatic failure.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Certican®
Arm1(conversion):Certican®+mycophenolate+prednisone
|
The conversion will be performed abruptly for all patients.
Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1).
Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.
|
Comparador activo: Tacrolimus or Cyclosporine
Arm2(maintained):Tacrolimus or Cyclosporine+mycophenolate+prednisone
|
Trough level should be between 100 and 200ng/ml.
Trough level should be between 5 and 10ng/ml.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change from baseline in viral load of hepatitis C virus at 12 months after randomization.
Periodo de tiempo: Baseline,Months 3, 6, 9 and 12 after randomization
|
HCV viremia will be measured by polymerase chain reaction (PCR)
|
Baseline,Months 3, 6, 9 and 12 after randomization
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Incidence of acute allograft rejection
Periodo de tiempo: Weeks 1, 2, 3, months 1, 3, 6, 9 and 12 after randomization
|
All patients will perform at least 07 protocol visits and should be performed renal biopsy during screening phase and during the follow up if present renal dysfunction or proteinuria.
|
Weeks 1, 2, 3, months 1, 3, 6, 9 and 12 after randomization
|
Incidence of significant infections
Periodo de tiempo: Weeks1, 2, 3 and months 1, 3, 6,9 and 12 after randomization
|
During the study visits the patient will be evaluated by a doctor and it will perform blood tests to assess their clinical conditions.
|
Weeks1, 2, 3 and months 1, 3, 6,9 and 12 after randomization
|
Development of proteinuria
Periodo de tiempo: Months 1, 3, 6, 9 and 12 after randomization
|
Spot urine sample for protein and creatinine will be performed.
|
Months 1, 3, 6, 9 and 12 after randomization
|
Development of malignance
Periodo de tiempo: Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization
|
Medical evaluation will be performed during the protocol visits and if necessary biopsy and exams of imaging to confirm any suspected.
|
Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization
|
Development of dyslipidemia
Periodo de tiempo: Months 1, 3, 6, 9 and 12 after randomization
|
Lipid levels: total cholesterol, HLD, LDL and triglycerides will be performed.
|
Months 1, 3, 6, 9 and 12 after randomization
|
Development of liver impairment
Periodo de tiempo: Months 1, 3, 6, 9, and 12 after randomization
|
Blood chemistry: TGO/AST, TGP/ALT , GGT and alkaline phosphatase will be performed.
|
Months 1, 3, 6, 9, and 12 after randomization
|
Development of post-transplant diabetes
Periodo de tiempo: Months 1, 3, 6, 9 and 12
|
Blood chemistry: Glucose will be performed.
|
Months 1, 3, 6, 9 and 12
|
Development of hypertension
Periodo de tiempo: Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization
|
Vital signs will be performed
|
Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization
|
Graft loss survival
Periodo de tiempo: Weeks 1, 2 , 3 and months 1, 3 ,6, 9 and 12 after randomization
|
Graft survival will be evaluated by our team doctor.
|
Weeks 1, 2 , 3 and months 1, 3 ,6, 9 and 12 after randomization
|
Patient survival
Periodo de tiempo: Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization
|
Subject survival will be evaluated by our team doctor
|
Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: MARIANA F RODRIGUES, PHARMACIST, Irmandade da Santa Casa de Misericórdia de Porto Alegre
- Director de estudio: DIEGO GNATTA, PHARMACIST, Irmandade da Santa Casa de Misericórdia de Porto Alegre
- Director de estudio: LARISSA S PACHECO, PHARMACIST, Irmandade da Santa Casa de Misericórdia de Porto Alegre
- Director de estudio: BRUNA D CARDOSO, PHARMACIST, Irmandade da Santa Casa de Misericórdia de Porto Alegre
- Director de estudio: RONIVAN L DAL PRA, PHARMACIST, Irmandade da Santa Casa de Misericórdia de Porto Alegre
Publicaciones y enlaces útiles
Publicaciones Generales
- Gallego R, Henriquez F, Oliva E, Camacho R, Hernandez R, Hortal L, Sablon N, Quintana B, Santana R, Gonzalez F, Palop L, Vega N. Switching to sirolimus in renal transplant recipients with hepatitis C virus: a safe option. Transplant Proc. 2009 Jul-Aug;41(6):2334-6. doi: 10.1016/j.transproceed.2009.06.064.
- Wagner D, Kniepeiss D, Schaffellner S, Jakoby E, Mueller H, Fahrleitner-Pammer A, Stiegler P, Tscheliessnigg KH, Iberer F. Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates. Int Immunopharmacol. 2010 Aug;10(8):990-3. doi: 10.1016/j.intimp.2010.05.006. Epub 2010 May 17.
- Benedetto, F. D.; Sandro, S. D.; Ballarin, R.; Guaraldi, G.; Gerunda, G. E. Rapamycin and HIV Replication in Liver Transplant Recipients. Transplantation, 9, 1040, 2010.
- Boletis JN, Iniotaki-Theodoraki A, Psichogiou M, Stamatiadis DN, Viglis JV, Kostakis A, Stavropoulos-Giokas C. Immune status in renal transplant recipients with hepatitis C virus infection. Transplant Proc. 2002 Dec;34(8):3205-8. doi: 10.1016/s0041-1345(02)03656-4. No abstract available.
- Ingsathit A, Thakkinstian A, Kantachuvesiri S, Sumethkul V. Different impacts of hepatitis B virus and hepatitis C virus on the outcome of kidney transplantation. Transplant Proc. 2007 Jun;39(5):1424-8. doi: 10.1016/j.transproceed.2007.02.068.
- Ridruejo E, Cusumano A, Diaz C, Davalos Michel M, Jost L, Jost h L, Soler Pujol G, Mando OG, Vilches A. Hepatitis C virus infection and outcome of renal transplantation. Transplant Proc. 2007 Dec;39(10):3127-30. doi: 10.1016/j.transproceed.2007.04.023.
- Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation. 2001 Jul 27;72(2):241-4. doi: 10.1097/00007890-200107270-00013.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Procesos Patológicos
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Síndrome de Respuesta Inflamatoria Sistémica
- Inflamación
- Enfermedades del HIGADO
- Infecciones por Flaviviridae
- Hepatitis, Viral, Humana
- Septicemia
- Infecciones por enterovirus
- Infecciones por Picornaviridae
- Hepatitis
- Hepatitis A
- Hepatitis C
- Viremia
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Inhibidores de enzimas
- Agentes antirreumáticos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes dermatológicos
- Agentes antifúngicos
- Inhibidores de calcineurina
- Tacrolimus
- Everolimus
- Ciclosporina
- Ciclosporinas
Otros números de identificación del estudio
- CRAD001
- CRAD001ABR20T (Otro identificador: NOVARTIS)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Hepatitis C
-
AbbVieTerminadoHepatitis C Crónica | Hepatitis C (VHC) | Hepatitis C Genotipo 1a
-
AbbVie (prior sponsor, Abbott)TerminadoHepatitis C Crónica | Hepatitis C Genotipo 1 | Hepatitis C (VHC)Estados Unidos, Australia, Canadá, Francia, Alemania, Nueva Zelanda, Puerto Rico, España, Reino Unido
-
Trek Therapeutics, PBCTerminadoHepatitis C Crónica | Hepatitis C Genotipo 1 | Hepatitis C (VHC) | Infección viral de la hepatitis CEstados Unidos, Nueva Zelanda
-
Trek Therapeutics, PBCTerminadoHepatitis C Crónica | Hepatitis C (VHC) | Hepatitis C Genotipo 4 | Infección viral de la hepatitis CEstados Unidos
-
AbbVieTerminadoHepatitis C Crónica | Hepatitis C (VHC) | Hepatitis C Genotipo 1a
-
AbbVieTerminadoVirus de la hepatitis C | Virus de la hepatitis C crónica
-
AbbVie (prior sponsor, Abbott)TerminadoHepatitis C | Infección crónica por hepatitis C | VHC | Hepatitis C Genotipo 1Estados Unidos
-
Humanity and Health Research CentreBeijing 302 HospitalTerminadoInfección crónica por hepatitis CPorcelana
-
University Health Network, TorontoTerminadoInfección crónica por hepatitis CCanadá
-
AbbVie (prior sponsor, Abbott)TerminadoHepatitis C | Infección crónica por hepatitis C | VHC | Hepatitis C Genotipo 1Estados Unidos, Puerto Rico
Ensayos clínicos sobre Everolimus
-
Novartis PharmaceuticalsTerminadoLinfangioleiomiomatosis (LAM) | Complejo de esclerosis tuberosa (TSC)Estados Unidos, Reino Unido, Alemania, Italia, Federación Rusa, Países Bajos, Japón, Canadá, Polonia, Francia, España
-
The Netherlands Cancer InstituteActivo, no reclutandoCarcinomas neuroendocrinosPaíses Bajos
-
German Breast GroupNovartisTerminadoCáncer de mama metastásicoAlemania
-
Novartis PharmaceuticalsTerminadoCarcinoma hepatocelularHong Kong, Taiwán, Tailandia
-
Novartis PharmaceuticalsTerminadoTumor neuroendocrino gastroenteropancreático del sistema pulmonar o gastroenteropancreáticoAlemania
-
University of LuebeckTerminadoEnfermedad de la arteria coronariaAlemania
-
Guangdong Provincial People's HospitalNovartisDesconocidoTumores neuroendocrinos | Tumor carcinoidePorcelana
-
Centre Leon BerardSuspendido
-
Asan Medical CenterTerminadoNeoplasia de estómagoCorea, república de
-
Leiden University Medical CenterDesconocidoCáncer de cabeza y cuelloPaíses Bajos